Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib as Neoadjuvant Treatment for Locally Advanced Thyroid Cancer
NCT05989425Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in differentiated thyroid cancer (DTC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 1 year. Started Aug 2023; status: recruiting.
02
Drugs
surufatinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT05989425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989425.